Cordyceps Militaris Strain Composition for Scalable Bioactive Consistency
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional methods for cultivating Cordyceps militaris face challenges in large-scale production, consistency of bioactive compound production, and variability due to small sporocarp size and inconsistent growth conditions, leading to reduced efficacy of products that often rely on highly processed extracts or isolated polysaccharide fractions.
Innovation Solution
Development of a novel strain, Cordyceps militaris M2-116-04, optimized for large-scale cultivation with enhanced bioactive compound production, utilizing liquid submerged fermentation techniques and organic grain substrates, ensuring consistent production of beta-glucans and cordycepin, and preserving a diverse array of biomolecules.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional cultivation methods are used for Cordyceps militaris, then the fungus can be grown, but large-scale production is difficult and consistency of bioactive compound production is poor
Solution Approach 1:
The patent applies parameter changes by optimizing cultivation conditions including temperature, humidity, substrate composition, and inoculation timing to achieve consistent bioactive compound production. The strain M2-116-04 was specifically selected and bred for its ability to produce consistent levels of cordycepin and beta-glucans under controlled conditions, resolving the contradiction between scalability and production consistency.
Solution Approach 2:
The patent uses copying by creating standardized cultivation protocols that can be replicated across multiple batches and locations. The optimized strain M2-116-04 serves as a template that can be propagated consistently, allowing large-scale production while maintaining reliable bioactive compound levels through standardized processing methods.
2Reliability
If highly processed extracts or isolated polysaccharide fractions are used, then product efficacy can be enhanced, but the complete spectrum of bioactive compounds is lost
Solution Approach 1:
The patent takes out the approach of using minimally processed whole mushroom formulations rather than highly processed extracts. By selecting and cultivating strain M2-116-04 specifically for high bioactive content in the whole mushroom, the patent achieves efficacy without losing the complete spectrum of compounds, thus resolving the contradiction between efficacy and compound diversity.
Solution Approach 2:
The patent employs composite materials by using whole mushroom formulations that contain multiple bioactive compounds working together. The strain M2-116-04 produces a composite profile including cordycepin, beta-glucans, and other secondary metabolites that maintain synergistic effects, avoiding the reduction to isolated fractions while preserving efficacy.
3Ease of manufacture
If conventional processing techniques are used, then the mushroom can be processed, but chemical composition is altered and complementary interactions among constituents are attenuated
Solution Approach 1:
The patent applies partial action by using minimal processing that preserves the integrity of the mushroom structure and its chemical composition. Rather than extensive processing, the patent uses gentle techniques that maintain the natural state of strain M2-116-04, preserving both chemical composition and synergistic interactions while still enabling manufacturability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The optimized strain M2-116-04 provides minimally processed, full-spectrum fungal formulations with enhanced prebiotic activity and immune support, overcoming the limitations of conventional methods by ensuring scalability and consistent health benefits.
Implementation Method 1
Cordyceps militaris fungus designated as strain M2-116-04 is not naturally occurring and is the product of human intervention that includes increased cordycepin (C) content in the sporocarp and biomass compared with other strains
Data Source
AI summary
Embodiments include a not naturally occurring strain of Cordyceps militaris fungus designated as strain M2-116-04 as deposited with the ATCC Patent Depository under the Budapest Treaty (10801 University Blvd, Manassas, VA 20110), on Jul. 11, 2024, with the unofficial ATCC Patent Deposit Designation No. PTA-127802, and the official deposit date of Jul. 11, 2024, and the official Patent Deposit Designation No. PTA-127802. The isolated mycelium is characterized by a phenotype having an abundance of sporocarps on top of a substrate and/or along a parameter of a bioreactor bag, and also characterized by a phenotype having fruiting initiation at or near 18 days after inoculation, a phenotype having sporocarps maturing at or near 55 days after inoculation, and/or a phenotype having a 10-to-15-day colonization time on hulled oats. Applications include functional foods, prebiotic formulations, and immune support products, with the strain available in powder, capsule, or drink mix forms.